INDUSTRY OVERVIEW
The Biologics is Growing at 8% and is expected to reach 1.2Trillion by 2031. Below mentioned are some of the dynamics shaping the Biologics .Biologics Market Size in (USD Million) CAGR Growth Rate 8%
| Study Period | 2019-2031 |
| Market Size (2023): | 550Billion |
| Market Size (2031): | 1.2Trillion |
| CAGR (2023 - 2031): | 8% |
| Fastest Growing Region | Asia-Pacific |
| Dominating Region | North America |
www.www.htfmarketinsights.com
A biologic drug (biologic) is a chemical derived from or containing components of living organisms. For the manufacture of new biologics, new technologies and novel therapies are emerging, indicating that the global biologics market has a bright future. Biologics are widely utilized to treat, diagnose, and cure a wide range of ailments, including cancer, chronic renal disease, autoimmune disorders, and infectious infections. Patenting, testing, safety, efficacy, and marketing are only a few of the laws and regulations that apply to biologics. Biotechnological approaches and other cutting-edge technologies are used to isolate biologics products from natural sources such as humans, animals, and microorganisms.
Need More Details on Market Players and Competitors?
DOWNLOAD Sample Report
Market Drivers:
The key drivers in the market include technological advancements, increasing demand by consumers for innovative products, and government-friendly policies. Our research company combines industry reports with expert interviews and market analysis tools to identify and quantify drivers such as these. We review the current trends and gather data from leading industry publications and market research firms to decipher exactly how these and other factors are encouraging or dampening market growth.
- The Rise In The Robust Pipeline Of Biologics
- Chronic Disease Incidence And Diagnosis Are On The Rise Across The Globe
Market Restraints:
Some of the restraints to market growth may include regulatory challenges, high production costs, and disruptions in the supply chain. Our sources for these limitations include the regulation filings, industry surveys, and direct contributions from active participants within this marketplace. Tracking policy updates and economic reports further helps us to determine what kind of effect these factors have on the industry.
- Regulatory Hurdles
Trends in the Market:
Among the trending ones are sustainability, digital transformation, and increasing importance of data analytics. Our research company is tracking these trends through the use of trend analysis tools, social media sentiment analysis, and industry benchmarking studies. Insights in emerging market preferences and technological advancements also come from surveys and focus groups.
- Pharmaceuticals
These include emerging markets, innovation in product development, and strategic partnerships. We identify these opportunities by performing market segmentation analysis, competitive landscape assessment, and investment trend evaluation. The data is collected based on industry reports, financial performance analysis for major players, and forecasting models for identifying future growth areas.
- Increases Funding In Developing Country
Check Out Prices
Get Price
Regulation Shaping the Healthcare Industry
The healthcare industry is significantly influenced by a complex framework of regulations designed to ensure patient safety, efficacy of treatments, and the overall quality of care. Key regulatory areas include drug approval processes, medical device standards, and healthcare data protection. These regulations aim to maintain high standards for clinical practices and safeguard public health.Major Regulatory Bodies Worldwide
1. U.S. Food and Drug Administration (FDA): In the United States, the FDA is a pivotal regulatory authority overseeing the approval and monitoring of pharmaceuticals, medical devices, and biologics. The FDA sets stringent standards for product safety and efficacy, which significantly impacts market entry and ongoing compliance for healthcare companies.2. European Medicines Agency (EMA): The EMA plays a crucial role in the European Union, evaluating and supervising medicinal products. It provides centralized approval for drugs and ensures that products meet rigorous safety and efficacy standards across member states.
3. Health Canada: This agency regulates pharmaceuticals and medical devices in Canada, ensuring that products are safe, effective, and of high quality. Health Canada's regulations are aligned with international standards but tailored to meet national health needs.
4. World Health Organization (WHO): While not a regulatory body in the traditional sense, the WHO sets international health standards and provides guidelines that influence national regulatory frameworks. It plays a key role in global health policy and emergency response.
5. National Medical Products Administration (NMPA): In China, the NMPA regulates the approval and supervision of drugs and medical devices, with an increasing focus on aligning with global standards and facilitating market access.
Request for Customization
Get Customization
SWOT Analysis in the Healthcare Industry
SWOT analysis in the healthcare industry involves a structured assessment of Strengths, Weaknesses, Opportunities, and Threats to identify strategic advantages and areas for improvement.• Strengths: Evaluates internal factors such as advanced technology, skilled personnel, and strong brand reputation. For example, a hospital with cutting-edge medical equipment and specialized staff is considered to have a strong competitive edge.
• Weaknesses: Identifies internal limitations like outdated facilities, regulatory compliance issues, or high operational costs. Weaknesses could include inefficient processes or lack of innovation.
• Opportunities: Assesses external factors that could drive growth, such as emerging medical technologies, expanding markets, or favorable government policies. Opportunities might involve partnerships or new service lines.
• Threats: Examines external challenges such as increasing competition, changing regulations, or economic downturns. Threats might include new entrants with disruptive technologies or stricter regulatory requirements.
Market Segmentation
Segmentation by Type
- Monoclonal Antibodies
- Gene Therapy
- Vaccines
- Recombinant Proteins
Biologics Market Segmentation by Type
www.htfmarketinsights.com
Segmentation by Application
- Healthcare
- Cancer Treatment
- Immunotherapy
- Autoimmune Diseases
- R&D
Biologics Market Segmentation by Application
www.htfmarketinsights.com
Regional Outlook
The North America currently holds a significant share of the market, primarily due to several key factors: increasing consumption rates, a burgeoning population, and robust economic momentum. These elements collectively drive demand, positioning this region as a leader in the market. On the other hand, Asia-Pacific is rapidly emerging as the fastest-growing area within the industry. This remarkable growth can be attributed to swift infrastructure development, the expansion of various industrial sectors, and a marked increase in consumer demand. These dynamics make this region a crucial player in shaping future market growth. In our report, we cover a comprehensive analysis of the regions and countries, includingRegions
- North America
- LATAM
- West Europe
- Central & Eastern Europe
- Northern Europe
- Southern Europe
- East Asia
- Southeast Asia
- South Asia
- Central Asia
- Oceania
- MEA
Fastest Growing Region
Asia-Pacific
Dominating Region
North America
The company consistently allocates significant resources to expand its research capabilities, develop new medical technologies, and enhance its pharmaceutical portfolio. Johnson & Johnson's investments in R&D, coupled with strategic acquisitions and partnerships, reinforce its position as a major contributor to advancements in healthcare. This focus on innovation and market expansion underscores the critical importance of the North American region in the global healthcare landscape.
- Merck & Co.
- Inc. (United States)
- AbbVie Inc. (United States)
- F. Hoffmann-La Roche AG (Switzerland)
- Johnson & Johnson (United States)
- Pfizer Inc. (United States)
- AstraZeneca (United Kingdom)
- ABLbio (South Korea)
- Adimmune (Taiwan)
- Helius (India)
Biologics Market Segmentation by Players
www.htfmarketinsights.com
Primary and Secondary Research
Primary research involves the collection of original data directly from sources in the healthcare industry. Approaches include the survey of health professionals, interviews with patients, focus groups, and clinical trials. This gives an overview of the current practice, the needs of the patient, and the interest in emerging trends. Firsthand information on the efficacy of new treatments, an assessment of market demand, and insight into changes in regulation can be sought only with primary research.Secondary Research: This is the investigation of existing information from a variety of sources, which may include industry reports, academic journals, government publications, and market research studies. Alfred secondary research empowers them to understand trends within industries, historical data, and competitive landscapes. It gives a wide view of the market dynamics and validates findings obtained from primary research. By combining both primary and secondary together, health organizations will be empowered to develop comprehensive strategies and make informed decisions based on a strong foundation built on data.
Report Infographics
|
Report Features |
Details |
|
Base Year |
2023 |
|
Based Year Market Size (2023) |
550Billion |
|
Historical Period |
2019 to 2023 |
|
CAGR (2023 to 2031) |
8% |
|
Forecast Period |
2023 to 2031 |
|
Forecasted Period Market Size (2031) |
1.2Trillion |
|
Scope of the Report |
Segmentation by Type
Segmentation by Application
|
|
Regions Covered |
North America, LATAM, West Europe,Central & Eastern Europe, Northern Europe, Southern Europe, East Asia, Southeast Asia, South Asia, Central Asia, Oceania, MEA |
|
Companies Covered |
Merck & Co., Inc. (United States), AbbVie Inc. (United States), F. Hoffmann-La Roche AG (Switzerland), Johnson & Johnson (United States), Pfizer Inc. (United States), AstraZeneca (United Kingdom), ABLbio (South Korea), Adimmune (Taiwan), Helius (India) |
|
Customization Scope |
15% Free Customization (For EG) |
|
Delivery Format |
PDF and Excel through Email |
Biologics - Table of Contents
Chapter 1: Market Preface
- 1.1 Global Biologics Market Landscape
- 1.2 Scope of the Study
- 1.3 Relevant Findings & Stakeholder Advantages
Chapter 2: Strategic Overview
- 2.1 Global Biologics Market Outlook
- 2.2 Total Addressable Market versus Serviceable Market
- 2.3 Market Rivalry Projection
Chapter 3 : Global Biologics Market Business Environment & Changing Dynamics
-
3.1 Growth Drivers
- 3.1.1 The rise in the Robust Pipeline of Biologics
- 3.1.2 Chronic Disease Incidence and Diagnosis are on the Rise across the Globe
-
3.2 Available Opportunities
- 3.2.1 Increases Funding In Developing Country
- 3.2.2 Inc
-
3.3 Influencing Trends
- 3.3.1 Pharmaceuticals
- 3.3.2 biotechnological research
-
3.4 Challenges
- 3.4.1 Regulatory hurdles
- 3.4.2 high R&D costs
- 3.5 Regional Dynamics
Need only Qualitative Analysis? Get Prices
Sectional Purchase
Chapter 4 : Global Biologics Industry Factors Assessment
- 4.1 Current Scenario
- 4.2 PEST Analysis
- 4.3 Business Environment - PORTER 5-Forces Analysis
- 4.3.1 Supplier Leverage
- 4.3.2 Bargaining Power of Buyers
- 4.3.3 Threat of Substitutes
- 4.3.4 Threat from New Entrant
- 4.3.5 Market Competition Level
- 4.4 Roadmap of Biologics Market
- 4.5 Impact of Macro-Economic Factors
- 4.6 Market Entry Strategies
- 4.7 Political and Regulatory Landscape
- 4.8 Supply Chain Analysis
- 4.9 Impact of Tariff War
Chapter 5: Biologics : Competition Benchmarking & Performance Evaluation
- 5.1 Global Biologics Market Concentration Ratio
- 5.1.1 CR4, CR8 and HH Index
- 5.1.2 % Market Share - Top 3
- 5.1.3 Market Holding by Top 5
- 5.2 Market Position of Manufacturers by Biologics Revenue 2023
- 5.3 Global Biologics Sales Volume by Manufacturers (2023)
- 5.4 BCG Matrix
- 5.4 Market Entropy
- 5.5 Ansoff Matrix
- 5.6 FPNV Positioning Matrix
Chapter 6: Global Biologics Market: Company Profiles
- 6.1 Merck & Co.
- 6.1.1 Merck & Co. Company Overview
- 6.1.2 Merck & Co. Product/Service Portfolio & Specifications
- 6.1.3 Merck & Co. Key Financial Metrics
- 6.1.4 Merck & Co. SWOT Analysis
- 6.1.5 Merck & Co. Development Activities
- 6.2 Inc. (United States)
- 6.3 AbbVie Inc. (United States)
- 6.4 F. Hoffmann-La Roche AG (Switzerland)
- 6.5 Johnson & Johnson (United States)
- 6.6 Pfizer Inc. (United States)
- 6.7 AstraZeneca (United Kingdom)
- 6.8 ABLbio (South Korea)
- 6.9 Adimmune (Taiwan)
- 6.10 Helius (India)
- 6.11 Innovent Biologics (China)
To View a Complete List of Players? Inquiry Now
Sectional Purchase
Chapter 7 : Global Biologics by Type & Application (2019-2031)
-
7.1 Global Biologics Market Revenue Analysis (USD Million) by Type (2019-2023)
- 7.1.1 Monoclonal Antibodies
- 7.1.2 Gene Therapy
- 7.1.3 Vaccines
- 7.1.4 Recombinant Proteins
- 7.1.5 Biosimilars
-
7.2 Global Biologics Market Revenue Analysis (USD Million) by Application (2019-2023)
- 7.2.1 Healthcare
- 7.2.2 Cancer Treatment
- 7.2.3 Immunotherapy
- 7.2.4 Autoimmune Diseases
- 7.2.5 R&D
- 7.3 Global Biologics Market Revenue Analysis (USD Million) by Type (2023-2031)
- 7.4 Global Biologics Market Revenue Analysis (USD Million) by Application (2023-2031)
Chapter 8 : North America Biologics Market Breakdown by Country, Type & Application
- 8.1 North America Biologics Market by Country (USD Million) & Sales Volume (Units) [2019-2023]
- 8.1.1 United States
- 8.1.2 Canada
-
8.2 North America Biologics Market by Type (USD Million) & Sales Volume (Units) [2019-2023]
- 8.2.1 Monoclonal Antibodies
- 8.2.2 Gene Therapy
- 8.2.3 Vaccines
- 8.2.4 Recombinant Proteins
- 8.2.5 Biosimilars
-
8.3 North America Biologics Market by Application (USD Million) & Sales Volume (Units) [2019-2023]
- 8.3.1 Healthcare
- 8.3.2 Cancer Treatment
- 8.3.3 Immunotherapy
- 8.3.4 Autoimmune Diseases
- 8.3.5 R&D
- 8.4 North America Biologics Market by Country (USD Million) & Sales Volume (Units) [2024-2031]
- 8.5 North America Biologics Market by Type (USD Million) & Sales Volume (Units) [2024-2031]
- 8.6 North America Biologics Market by Application (USD Million) & Sales Volume (Units) [2024-2031]
Looking for Section Purchase? Get Quote Now
Sectional Purchase
Chapter 9 : LATAM Biologics Market Breakdown by Country, Type & Application
- 9.1 LATAM Biologics Market by Country (USD Million) & Sales Volume (Units) [2019-2023]
- 9.1.1 Brazil
- 9.1.2 Argentina
- 9.1.3 Chile
- 9.1.4 Mexico
- 9.1.5 Rest of LATAM
-
9.2 LATAM Biologics Market by Type (USD Million) & Sales Volume (Units) [2019-2023]
- 9.2.1 Monoclonal Antibodies
- 9.2.2 Gene Therapy
- 9.2.3 Vaccines
- 9.2.4 Recombinant Proteins
- 9.2.5 Biosimilars
-
9.3 LATAM Biologics Market by Application (USD Million) & Sales Volume (Units) [2019-2023]
- 9.3.1 Healthcare
- 9.3.2 Cancer Treatment
- 9.3.3 Immunotherapy
- 9.3.4 Autoimmune Diseases
- 9.3.5 R&D
- 9.4 LATAM Biologics Market by Country (USD Million) & Sales Volume (Units) [2024-2031]
- 9.5 LATAM Biologics Market by Type (USD Million) & Sales Volume (Units) [2024-2031]
- 9.6 LATAM Biologics Market by Application (USD Million) & Sales Volume (Units) [2024-2031]
Chapter 10 : West Europe Biologics Market Breakdown by Country, Type & Application
- 10.1 West Europe Biologics Market by Country (USD Million) & Sales Volume (Units) [2019-2023]
- 10.1.1 Germany
- 10.1.2 France
- 10.1.3 Benelux
- 10.1.4 Switzerland
- 10.1.5 Rest of West Europe
-
10.2 West Europe Biologics Market by Type (USD Million) & Sales Volume (Units) [2019-2023]
- 10.2.1 Monoclonal Antibodies
- 10.2.2 Gene Therapy
- 10.2.3 Vaccines
- 10.2.4 Recombinant Proteins
- 10.2.5 Biosimilars
-
10.3 West Europe Biologics Market by Application (USD Million) & Sales Volume (Units) [2019-2023]
- 10.3.1 Healthcare
- 10.3.2 Cancer Treatment
- 10.3.3 Immunotherapy
- 10.3.4 Autoimmune Diseases
- 10.3.5 R&D
- 10.4 West Europe Biologics Market by Country (USD Million) & Sales Volume (Units) [2024-2031]
- 10.5 West Europe Biologics Market by Type (USD Million) & Sales Volume (Units) [2024-2031]
- 10.6 West Europe Biologics Market by Application (USD Million) & Sales Volume (Units) [2024-2031]
Chapter 11 : Central & Eastern Europe Biologics Market Breakdown by Country, Type & Application
- 11.1 Central & Eastern Europe Biologics Market by Country (USD Million) & Sales Volume (Units) [2019-2023]
- 11.1.1 Bulgaria
- 11.1.2 Poland
- 11.1.3 Hungary
- 11.1.4 Romania
- 11.1.5 Rest of CEE
-
11.2 Central & Eastern Europe Biologics Market by Type (USD Million) & Sales Volume (Units) [2019-2023]
- 11.2.1 Monoclonal Antibodies
- 11.2.2 Gene Therapy
- 11.2.3 Vaccines
- 11.2.4 Recombinant Proteins
- 11.2.5 Biosimilars
-
11.3 Central & Eastern Europe Biologics Market by Application (USD Million) & Sales Volume (Units) [2019-2023]
- 11.3.1 Healthcare
- 11.3.2 Cancer Treatment
- 11.3.3 Immunotherapy
- 11.3.4 Autoimmune Diseases
- 11.3.5 R&D
- 11.4 Central & Eastern Europe Biologics Market by Country (USD Million) & Sales Volume (Units) [2024-2031]
- 11.5 Central & Eastern Europe Biologics Market by Type (USD Million) & Sales Volume (Units) [2024-2031]
- 11.6 Central & Eastern Europe Biologics Market by Application (USD Million) & Sales Volume (Units) [2024-2031]
Chapter 12 : Northern Europe Biologics Market Breakdown by Country, Type & Application
- 12.1 Northern Europe Biologics Market by Country (USD Million) & Sales Volume (Units) [2019-2023]
- 12.1.1 The United Kingdom
- 12.1.2 Sweden
- 12.1.3 Norway
- 12.1.4 Baltics
- 12.1.5 Ireland
- 12.1.6 Rest of Northern Europe
-
12.2 Northern Europe Biologics Market by Type (USD Million) & Sales Volume (Units) [2019-2023]
- 12.2.1 Monoclonal Antibodies
- 12.2.2 Gene Therapy
- 12.2.3 Vaccines
- 12.2.4 Recombinant Proteins
- 12.2.5 Biosimilars
-
12.3 Northern Europe Biologics Market by Application (USD Million) & Sales Volume (Units) [2019-2023]
- 12.3.1 Healthcare
- 12.3.2 Cancer Treatment
- 12.3.3 Immunotherapy
- 12.3.4 Autoimmune Diseases
- 12.3.5 R&D
- 12.4 Northern Europe Biologics Market by Country (USD Million) & Sales Volume (Units) [2024-2031]
- 12.5 Northern Europe Biologics Market by Type (USD Million) & Sales Volume (Units) [2024-2031]
- 12.6 Northern Europe Biologics Market by Application (USD Million) & Sales Volume (Units) [2024-2031]
Chapter 13 : Southern Europe Biologics Market Breakdown by Country, Type & Application
- 13.1 Southern Europe Biologics Market by Country (USD Million) & Sales Volume (Units) [2019-2023]
- 13.1.1 Spain
- 13.1.2 Italy
- 13.1.3 Portugal
- 13.1.4 Greece
- 13.1.5 Rest of Southern Europe
-
13.2 Southern Europe Biologics Market by Type (USD Million) & Sales Volume (Units) [2019-2023]
- 13.2.1 Monoclonal Antibodies
- 13.2.2 Gene Therapy
- 13.2.3 Vaccines
- 13.2.4 Recombinant Proteins
- 13.2.5 Biosimilars
-
13.3 Southern Europe Biologics Market by Application (USD Million) & Sales Volume (Units) [2019-2023]
- 13.3.1 Healthcare
- 13.3.2 Cancer Treatment
- 13.3.3 Immunotherapy
- 13.3.4 Autoimmune Diseases
- 13.3.5 R&D
- 13.4 Southern Europe Biologics Market by Country (USD Million) & Sales Volume (Units) [2024-2031]
- 13.5 Southern Europe Biologics Market by Type (USD Million) & Sales Volume (Units) [2024-2031]
- 13.6 Southern Europe Biologics Market by Application (USD Million) & Sales Volume (Units) [2024-2031]
Chapter 14 : East Asia Biologics Market Breakdown by Country, Type & Application
- 14.1 East Asia Biologics Market by Country (USD Million) & Sales Volume (Units) [2019-2023]
- 14.1.1 China
- 14.1.2 Japan
- 14.1.3 South Korea
- 14.1.4 Taiwan
- 14.1.5 Others
-
14.2 East Asia Biologics Market by Type (USD Million) & Sales Volume (Units) [2019-2023]
- 14.2.1 Monoclonal Antibodies
- 14.2.2 Gene Therapy
- 14.2.3 Vaccines
- 14.2.4 Recombinant Proteins
- 14.2.5 Biosimilars
-
14.3 East Asia Biologics Market by Application (USD Million) & Sales Volume (Units) [2019-2023]
- 14.3.1 Healthcare
- 14.3.2 Cancer Treatment
- 14.3.3 Immunotherapy
- 14.3.4 Autoimmune Diseases
- 14.3.5 R&D
- 14.4 East Asia Biologics Market by Country (USD Million) & Sales Volume (Units) [2024-2031]
- 14.5 East Asia Biologics Market by Type (USD Million) & Sales Volume (Units) [2024-2031]
- 14.6 East Asia Biologics Market by Application (USD Million) & Sales Volume (Units) [2024-2031]
Chapter 15 : Southeast Asia Biologics Market Breakdown by Country, Type & Application
- 15.1 Southeast Asia Biologics Market by Country (USD Million) & Sales Volume (Units) [2019-2023]
- 15.1.1 Vietnam
- 15.1.2 Singapore
- 15.1.3 Thailand
- 15.1.4 Malaysia
- 15.1.5 Indonesia
- 15.1.6 Philippines
- 15.1.7 Rest of SEA Countries
-
15.2 Southeast Asia Biologics Market by Type (USD Million) & Sales Volume (Units) [2019-2023]
- 15.2.1 Monoclonal Antibodies
- 15.2.2 Gene Therapy
- 15.2.3 Vaccines
- 15.2.4 Recombinant Proteins
- 15.2.5 Biosimilars
-
15.3 Southeast Asia Biologics Market by Application (USD Million) & Sales Volume (Units) [2019-2023]
- 15.3.1 Healthcare
- 15.3.2 Cancer Treatment
- 15.3.3 Immunotherapy
- 15.3.4 Autoimmune Diseases
- 15.3.5 R&D
- 15.4 Southeast Asia Biologics Market by Country (USD Million) & Sales Volume (Units) [2024-2031]
- 15.5 Southeast Asia Biologics Market by Type (USD Million) & Sales Volume (Units) [2024-2031]
- 15.6 Southeast Asia Biologics Market by Application (USD Million) & Sales Volume (Units) [2024-2031]
Chapter 16 : South Asia Biologics Market Breakdown by Country, Type & Application
- 16.1 South Asia Biologics Market by Country (USD Million) & Sales Volume (Units) [2019-2023]
- 16.1.1 India
- 16.1.2 Bangladesh
- 16.1.3 Others
-
16.2 South Asia Biologics Market by Type (USD Million) & Sales Volume (Units) [2019-2023]
- 16.2.1 Monoclonal Antibodies
- 16.2.2 Gene Therapy
- 16.2.3 Vaccines
- 16.2.4 Recombinant Proteins
- 16.2.5 Biosimilars
-
16.3 South Asia Biologics Market by Application (USD Million) & Sales Volume (Units) [2019-2023]
- 16.3.1 Healthcare
- 16.3.2 Cancer Treatment
- 16.3.3 Immunotherapy
- 16.3.4 Autoimmune Diseases
- 16.3.5 R&D
- 16.4 South Asia Biologics Market by Country (USD Million) & Sales Volume (Units) [2024-2031]
- 16.5 South Asia Biologics Market by Type (USD Million) & Sales Volume (Units) [2024-2031]
- 16.6 South Asia Biologics Market by Application (USD Million) & Sales Volume (Units) [2024-2031]
Chapter 17 : Central Asia Biologics Market Breakdown by Country, Type & Application
- 17.1 Central Asia Biologics Market by Country (USD Million) & Sales Volume (Units) [2019-2023]
- 17.1.1 Kazakhstan
- 17.1.2 Tajikistan
- 17.1.3 Others
-
17.2 Central Asia Biologics Market by Type (USD Million) & Sales Volume (Units) [2019-2023]
- 17.2.1 Monoclonal Antibodies
- 17.2.2 Gene Therapy
- 17.2.3 Vaccines
- 17.2.4 Recombinant Proteins
- 17.2.5 Biosimilars
-
17.3 Central Asia Biologics Market by Application (USD Million) & Sales Volume (Units) [2019-2023]
- 17.3.1 Healthcare
- 17.3.2 Cancer Treatment
- 17.3.3 Immunotherapy
- 17.3.4 Autoimmune Diseases
- 17.3.5 R&D
- 17.4 Central Asia Biologics Market by Country (USD Million) & Sales Volume (Units) [2024-2031]
- 17.5 Central Asia Biologics Market by Type (USD Million) & Sales Volume (Units) [2024-2031]
- 17.6 Central Asia Biologics Market by Application (USD Million) & Sales Volume (Units) [2024-2031]
Chapter 18 : Oceania Biologics Market Breakdown by Country, Type & Application
- 18.1 Oceania Biologics Market by Country (USD Million) & Sales Volume (Units) [2019-2023]
- 18.1.1 Australia
- 18.1.2 New Zealand
- 18.1.3 Others
-
18.2 Oceania Biologics Market by Type (USD Million) & Sales Volume (Units) [2019-2023]
- 18.2.1 Monoclonal Antibodies
- 18.2.2 Gene Therapy
- 18.2.3 Vaccines
- 18.2.4 Recombinant Proteins
- 18.2.5 Biosimilars
-
18.3 Oceania Biologics Market by Application (USD Million) & Sales Volume (Units) [2019-2023]
- 18.3.1 Healthcare
- 18.3.2 Cancer Treatment
- 18.3.3 Immunotherapy
- 18.3.4 Autoimmune Diseases
- 18.3.5 R&D
- 18.4 Oceania Biologics Market by Country (USD Million) & Sales Volume (Units) [2024-2031]
- 18.5 Oceania Biologics Market by Type (USD Million) & Sales Volume (Units) [2024-2031]
- 18.6 Oceania Biologics Market by Application (USD Million) & Sales Volume (Units) [2024-2031]
Chapter 19 : MEA Biologics Market Breakdown by Country, Type & Application
- 19.1 MEA Biologics Market by Country (USD Million) & Sales Volume (Units) [2019-2023]
- 19.1.1 Turkey
- 19.1.2 South Africa
- 19.1.3 Egypt
- 19.1.4 UAE
- 19.1.5 Saudi Arabia
- 19.1.6 Israel
- 19.1.7 Rest of MEA
-
19.2 MEA Biologics Market by Type (USD Million) & Sales Volume (Units) [2019-2023]
- 19.2.1 Monoclonal Antibodies
- 19.2.2 Gene Therapy
- 19.2.3 Vaccines
- 19.2.4 Recombinant Proteins
- 19.2.5 Biosimilars
-
19.3 MEA Biologics Market by Application (USD Million) & Sales Volume (Units) [2019-2023]
- 19.3.1 Healthcare
- 19.3.2 Cancer Treatment
- 19.3.3 Immunotherapy
- 19.3.4 Autoimmune Diseases
- 19.3.5 R&D
- 19.4 MEA Biologics Market by Country (USD Million) & Sales Volume (Units) [2024-2031]
- 19.5 MEA Biologics Market by Type (USD Million) & Sales Volume (Units) [2024-2031]
- 19.6 MEA Biologics Market by Application (USD Million) & Sales Volume (Units) [2024-2031]
Chapter 20: Research Findings & Conclusion
- 20.1 Key Findings
- 20.2 Conclusion
Chapter 21: Methodology and Data Source
-
21.1 Research Methodology & Approach
- 21.1.1 Research Program/Design
- 21.1.2 Market Size Estimation
- 21.1.3 Market Breakdown and Data Triangulation
-
21.2 Data Source
- 21.2.1 Secondary Sources
- 21.2.2 Primary Sources
Chapter 22: Appendix & Disclaimer
- 22.1 Acronyms & bibliography
- 22.2 Disclaimer
Frequently Asked Questions (FAQ):
The Biologics market is estimated to derive a market size of 1.2Trillion by 2031.
The Biologics Market is predicted to grow at a CAGR of 8%.
The changing dynamics and trends such as Pharmaceuticals, Biotechnological Research are seen as major Game Changer in Global Biologics Market.
The leaders in the Global Biologics Market such as Merck & Co., Inc. (United States), AbbVie Inc. (United States), F. Hoffmann-La Roche AG (Switzerland), Johnson & Johnson (United States), Pfizer Inc. (United States), AstraZeneca (United Kingdom), ABLbio (South Korea), Adimmune (Taiwan), Helius (India), Innovent Biologics (China) are targeting innovative and differentiated growth drivers some of them are The Rise In The Robust Pipeline Of Biologics,,
Chronic Disease Incidence And Diagnosis Are On The Rise Across The Globe,,
Increased Global Adoption Of Novel Biologics Drugs And Therapies
As Industry players prepare to scale up, Biologics Market sees major concern such as Regulatory Hurdles, High R&D Costs.
The market opportunity is clear from the flow of investment into Global Biologics Market, some of them are Increases Funding In Developing Country,,
Increasing Drug Manufactures In Developing Country.
Biologics Market identifies market share by players along with the concentration rate using CR4, CR8 Index to determine leading and emerging competitive players such as Merck & Co., Inc. (United States), AbbVie Inc. (United States), F. Hoffmann-La Roche AG (Switzerland), Johnson & Johnson (United States), Pfizer Inc. (United States), AstraZeneca (United Kingdom), ABLbio (South Korea), Adimmune (Taiwan), Helius (India), Innovent Biologics (China).
Research paper of Global Biologics Market shows that companies are making better progress than their supply chain peers –including suppliers, majorly in end-use applications such as Healthcare, Cancer Treatment, Immunotherapy, Autoimmune Diseases, R&D.
The Global Biologics Market Study is segmented by Monoclonal Antibodies, Gene Therapy, Vaccines, Recombinant Proteins, Biosimilars.
The Global Biologics Market Study includes regional breakdown as North America, LATAM, West Europe,Central & Eastern Europe, Northern Europe, Southern Europe, East Asia, Southeast Asia, South Asia, Central Asia, Oceania, MEA
The Biologics Market is studied from 2019 - 2031.
A biologic drug (biologic) is a chemical derived from or containing components of living organisms. For the manufacture of new biologics, new technologies and novel therapies are emerging, indicating that the global biologics market has a bright future. Biologics are widely utilized to treat, diagnose, and cure a wide range of ailments, including cancer, chronic renal disease, autoimmune disorders, and infectious infections. Patenting, testing, safety, efficacy, and marketing are only a few of the laws and regulations that apply to biologics. Biotechnological approaches and other cutting-edge technologies are used to isolate biologics products from natural sources such as humans, animals, and microorganisms.
